Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Melanoma 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Breast Neoplasms 1

Interventions

Cisplatin 32human papillomavirus vaccine, L1 type 16, 18 16Brachytherapy 15Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 12Paclitaxel 11Bevacizumab 11pembrolizumab 10Platinum 91,2-diaminocyclohexaneplatinum II citrate 9Topotecan 8Radiotherapy, Intensity-Modulated 8Radiation 8Papillomavirus Vaccines 8atezolizumab 6Gemcitabine 6Fluorodeoxyglucose F18 6Cyclophosphamide 6tisotumab vedotin 5fludarabine phosphate 5fludarabine 5aldesleukin 5Taxes 5Radiotherapy 5Magnetic Resonance Spectroscopy 5Carboplatin 5Vaccines, Synthetic 4Nivolumab 4Immunoglobulin G 4Disulfides 4Colposcopy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Uterine Cervical Neoplasms × GSK2141795 × Clear all
NCT01958112 2019-05-31

GSK1120212+GSK2141795 for Cervical Cancer

Dana-Farber Cancer Institute

Phase 2 Terminated
14 enrolled 10 charts
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡